Questionable Efficacy of Therapeutic Antibodies in the Treatment of Anthrax

Inhalational anthrax caused by Bacillus anthracis , a spore-forming Gram-positive bacterium, is a highly lethal infection. Antibodies targeting the protective antigen (PA) binding component of the toxins have recently been authorized as an adjunct to antibiotics, although no conclusive evidence demo...

Full description

Saved in:

Bibliographic Details
Published in:	mSphere Vol. 4; no. 3; pp. e00282 - 19
Main Authors:	Tournier, Jean-Nicolas, Rougeaux, Clémence, Biot, Fabrice V., Goossens, Pierre L.
Format:	Journal Article
Language:	English
Published:	United States American Society for Microbiology 19.06.2019
Subjects:	Animal models Animals Anthrax Anthrax - immunology Anthrax - therapy Antibiotics Antibodies Antibodies, Bacterial Antibodies, Bacterial - therapeutic use Antibodies, Monoclonal Antibodies, Monoclonal - therapeutic use Antigens Antigens, Bacterial Antigens, Bacterial - immunology Antitoxins Antitoxins - therapeutic use Bacillus anthracis Bacillus anthracis - immunology Bacterial Toxins Bacterial Toxins - immunology Disease Models, Animal Drug Evaluation, Preclinical Edema Humans Immunoglobulins Immunotherapy Infections Kinases Life Sciences Monoclonal antibodies Opinion/Hypothesis Patients Protective antigen Respiratory Tract Infections Respiratory Tract Infections - immunology Respiratory Tract Infections - therapy Sepsis Studies Therapeutics and Prevention Toxins Vaccines France United States > US antitoxins anthrax protective antigen toxins monoclonal antibodies
ISSN:	2379-5042, 2379-5042
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!